Sterling Pharma seals acquisition of bioconjugation specialist ADC

Sterling Pharma's Deeside facility

By integrating its HPAPI capabilities with those at ADC Biotechnologies' Deeside facility, small molecule CDMO will be able to offer the development and manufacturing of toxin linkers

ADC Biotechnologies' Deeside facility in North Wales will rebrand to become part of the Sterling Pharma Solutions international network.

Sterling said it will establish a centre of excellence for bioconjugation and antibody drug conjugate development and manufacturing services at the site.

A multimillion-pound investment will support the growth of the company’s ADC capabilities, which will include growing and developing the existing bioconjugation technical services team and expanding the analytical services team, particularly in the cGMP area. In addition, the team will develop and establish cGMP bioconjugation/ADC manufacturing at Deeside in 2022.

According to Kevin Cook, CEO at Sterling Pharma Solutions, the investment will enable the CDMO to offer a wider portfolio of services to its customers in the "fast growing" ADC and bioconjugation market.

"Integrating our HPAPI capabilities with the expertise already found at Deeside mean that we will also be able to offer the development and manufacture of toxin linkers," he said.